Budesonide may be effective for slowing renal function decline in patients with IgA nephropathy

1. Reduction in time-weighted glomerular filtration rate (GFR) decline was significantly greater in Nefecon versus placebo. 2. Majority of adverse events were mild-to-moderate in nature with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: IgA nephropathy is a chronic immune-mediated kidney disease with marked proteinuria. Nefecon, a novel, targeted-release form of budesonide, is

Related Keywords

,Rating Level ,Intensive Supportive Care ,Between Sept ,Budesonide ,Iga Nephropathy ,Kidney Failure ,Nefecon ,Nephrology ,Primary Iga Nephropathy ,Rheumatology ,Chronic Disease ,